Primary mediastinal large B-cell lymphoma(PMBCL)is an aggressive B-cell lympho-ma originating from the thymus,which has different clinical and biological characteristics from diffuse large B-cell lymphoma,NOS.PMBCL tends to occur in young women,usually presenting as a large anteri-or mediastinal mass.Most patients are in stage Ⅰ-Ⅱ at the time of presentation.There is no standard prog-nostic scoring system for PMBCL.Immunochemotherapy is commonly used in the treatment of PMBCL,but the optimal first-line treatment has not been determined,and the status of radiotherapy is controversial.The value of PET-CT guided therapy needs to be further verified.Relapsed/refractory PMBCL has a poor prognosis,while novel therapies such as PD-1 inhibitors,brentuximab vedotin,and CAR-T can help im-prove survival in these patients.
维普
万方数据
